Dr John A Snowden BSc (Hons), MBChB, MD, FRCP, FRCPath

Consultant Haematologist and Honorary Reader
Department of Haematology
Sheffield Teaching Hospitals NHS Foundation Trust

Tel: +44 (0) 114 271 3357 (Secretary)
Fax: +44 (0) 114 271 3997

Email: john.snowden@sth.nhs.uk

Biography

I graduated from the University of Leeds in 1989 and trained in Internal Medicine and Haematology in the UK, New Zealand and Australia. In 2002, I was appointed as Consultant Haematologist & Director of Blood and Marrow Transplantation (BMT) in the Sheffield Teaching Hospitals NHS Foundation Trust, and subsequently worked as Lead Clinician in Haemato-oncology for the Trust (2002-07) and Cancer Network (2007-10). My principal focus is the day-to-day provision and strategic development of tertiary level haematological cancer and BMT services (autologous, allogeneic and cord blood) for Sheffield and the North Trent Cancer Network region (covering approximately 2 million).  In April 2012, we became the first Anthony Nolan collection centre outside London.  In conjunction with my NHS roles, and my Honorary Reader status with the Department of Oncology, University of Sheffield, I endeavour to contribute to research and educational activity in Haemato-oncology and Stem Cell Transplantation. I have published around 100 scientific and clinical articles, including around 70 original observations, and 30 reviews and book chapters, and led on key national and international clinical guidelines. I am secretary to the EBMT Autoimmune Disease Working Party and current Medical Director for the JACIE organisation, which oversees the accreditation of BMT programmes throughout Europe. I am active in multicentre clinical trials and a member of the NCRI Haemato-oncology Clinical Studies Group (CSG) and the executive committee of the UK Myelome Forum (UKMF).

Academic Interests

• Blood,  marrow and umbilical cord derived haematopoietic stem cells in cancer and non-malignant disorders
• Physical and psychological late effects in survivors of cancer treatment and BMT
• Multiple myeloma, from cell biology to supportive care and survivorship research
• Clinical and laboratory studies in leukaemia and other haematological cancers
• Quality and  health economics in haemato-oncology and BMT

Professional Activities

• Medical Director, JACIE Organisation (2012-); Co-Chair of FACT-JACIE Clinical Standards Sub-committee (2007-present) – producing 4th and 5th Editions of FACT-JACIE Standards; FACT-JACIE HLA Typing Accreditation Committee (2012-)

• Secretary to the EBMT Working Party for Autoimmune Diseases (2010)

• NCRI Clinical Studies Group in Haematological Oncology, Member by appointment (2008-)

• UK Myeloma Forum (UKMF) Executive by national election (Guidelines, Website lead, 2010-)

• Member of NCEPOD Working Group for Systemic Anti-Cancer Chemotherapy, resulting in publication of report ‘Systemic Anti-Cancer Therapy: For better, for worse?’ in 2008

• British Society for Blood and Marrow Transplantation (BSBMT) Work - Educational Sub-committee, Indications Sub-committee

• Peer reviewer for scientific journals including: The Lancet, Bone Marrow Transplantation, British Journal of Haematology, International Journal of Laboratory Haematology, Leukemia Research, Arthritis & Rheumatism, Journal of Rheumatology, Journal of Infection, Human Immunology, Clinical Rheumatology, British Journal of Anaesthesia, European Journal of Neurology, Cell Transplantation

• Peer reviewer for grant awarding bodies including: Medical Research Council (MRC), Leukaemia & Lymphoma Research (LLR), Cancer Research UK (CRUK) European League against Rheumatism (EULAR), Arthritis Research Campaign (ARC), Raynaud’s and Scleroderma Society, and others

• Peer reviewer for conference abstracts e.g. EBMT, ASH and national conferences

• Editorial Board Member: International Journal of Laboratory Haematology (2006-), Pathologie-Biologie (2012-)

• Clinical Co-investigator for NCRI portfolio multicentre trials; ‘Myeloma X’ trial, TRYMS trial, UKALL60+ Trial

• DMEC and Trial Steering Group Work; Anti-CD66 Trial; Targeted radiotherapy with conditioning prior to haematopoietic stem cell transplantation (University of Southampton); Trial of HLA epitope matched platelet transfusion in aplastic anaemia and MDS patients; (NHBST) ASTIMS and ASTIC studies (EBMT).

Key Publications 2010-2012

Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, Clark RE, Kazmi M, Abinun M, Jackson G, Mackinnon S, Russell N, Cook G, on behalf of the BSBMT Clinical Trials Committee. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune disorders: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. British Journal of Haematology 2012; 157:742-6

Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C, Hawkey CJ, van Laar JM, Labopin M, Mancardi G, Martin R, Moore JJ, Passweg J, Peters C, Rabusin M, Rovira M, Farge D on behalf of the EBMT Autoimmune Disease (ADWP) and Paediatric Diseases (PDWP) Working Parties. Haematopoietic stem cell transplantation (HSCT) in severe auto-immune diseases (ADs): updated guidelines of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation 2012; 47:770-90

Bansal T, Garg A, Snowden JA, McKane W. Defining the role of renal transplantation in multiple myeloma and other plasma cell dyscrasias. Nephron 2012; in press

Patrick KL, Snowden JA, Wilson G, Collins N, Dalley CD. Long-term lympho-haematopoietic reconstitution by umbilical cord blood stem cells following primary graft failure and autologous rescue. British Journal of Haematology 2012; 158(3):419-20

Taylor N, Absolom K, Snowden J, Eiser C; Late Effects Group Sheffield. Need for psychological follow-up among young adult survivors of childhood cancer. European Journal of Cancer Care (England) 2012; 21(1):52-8

Goodyear OC, Dennis M, Loke J, Jilani N, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden J, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock C. Azacitidine Induces Expansion of Regulatory T Cells and Induces a Tumor Antigen Specific Response after Allogeneic Stem Cell Transplantation: a Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response Blood 2011; 119:3361-9

Snowden JA, Ahmedzai SH, Ashcroft J, D’Sa S, Littlewood T, Low E, Lucraft H, Maclean R, Feyler S, Pratt G, Bird JM on behalf of BCSH and UK Myeloma Forum. Guidelines for Supportive Care in Myeloma 2011. British Journal of Haematology; 2011; 154(1):76-103

Bird J, Owen R, d’Sa S, Snowden JA, Littlewood T, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Cavenagh J, Low E, Behrens J on behalf of BCSH and UK Myeloma Forum. Guidelines on the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011; 54(1):32-75

Daikeler T, Labopin M, Di Gioia M, Abinum M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Gungor T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P, Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D; EBMT Autoimmune Disease Working Party. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011; 118(6):1693-8

Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Roddie H, Clark A, Parker A, Liakopoulou E, Pettengel R, Snowden J, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution. Blood 2010; 116(16):3080-8

Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro P, Mancardi G, Kozak T, Farge D, Madan J, Rafia R, Akehurst R, Snowden J. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplantation 2010; 45:1014-21

Greenfield DM, Walters S, Coleman RE, Hancock BW, Snowden JA, Shalet S, DeRogatis LR, Ross RJM. Health Related Quality of Life, Self-esteem, Fatigue and Sexual Function in Young Men after Cancer: a Controlled Cross-Sectional Study Cancer 2010; 116:1592-601

Arachchillage DR, Dalley CD, Reilly JT, Wilson G, Collins N, Snowden JA.  Long-term dual donor derived haematopoietic reconstitution following double unrelated cord blood transplantation - single unit dominance is not always the case.  British Journal of Haematology 2010; 149(2):298-9